BioCentury | Sep 10, 2020
Product Development

Master protocols should not be a one-off phenomenon confined to COVID-19

...the specified mutations are assigned to Darzalex daratumumab...
BioCentury | Sep 9, 2020
Product Development

Networking that fueled COVID-19 response should spill into digital sciences and more, says Genmab’s van de Winkel: a BioCentury audio interview

...advocate of master protocol trials, where Genmab has used basket trial formats to study Darzalex daratumumab...
...course, is very different. You can also include in basket studies, massively like daratumumab, or Darzalex...
...company to move your drug to the next phase. Or even as we did for daratumumab...
BioCentury | Sep 8, 2020
Product Development

Biopharmas must address the reality of racial disparities in health outcomes exposed by COVID-19

...differences by investigating the use of Darzalex daratumumab...
...patients. Nevertheless, Flatiron found that adoption of Darzalex...
BioCentury | Aug 20, 2020
Regulation

Pandemic could give advantage to newly approved MS latecomer ofatumumab

...Up Commercial Launches”). FDA approved subcutaneous formulations of two cancer drugs earlier this year: Darzalex daratumumab...
BioCentury | Jul 10, 2020
Finance

How buysiders are sizing up commercial launches during the pandemic

...a subcutaneous drug delivery technology from Halozyme Therapeutics Inc. (NASDAQ:HALO) beat forecasts. For Darzalex Faspro daratumumab...
BioCentury | Jul 1, 2020
Regulation

June 30 Quick Takes: Another first for Ultragenyx; plus approvals for Genentech’s Phesgo, Keytruda, Bavencio and Ultomiris

...or less. Phesgo is the second drug approved using the Enhanze technology this year (see “Darzalex...
BioCentury | Jun 6, 2020
Product Development

June 5 Quick Takes: Merck, Tetraphase-Melinta, Apeiron, Neurasic, Jounce, Genmab-J&J

...European approval of subcutaneous Darzalex The EC approved a subcutaneous formulation of anti-CD38 mAb Darzalex daratumumab...
...relapsed-refractory multiple myeloma indications approved for IV administration. FDA approved the formulation in May (see “Darzalex...
BioCentury | Jun 2, 2020
Product Development

Sanofi makes case for why its first cancer drug in a decade can take on Darzalex

...of death by 47% and led to a complete response of 40%. In contrast, Darzalex daratumumab...
...pharma has launched in more than a decade, and it faces an uphill battle against Darzalex...
BioCentury | May 1, 2020
Regulation

As first subcutaneous anti-CD38 mAb, Darzalex Faspro secures J&J’s lead in MM, shaves hours off infusion time

...the drugs take hours to infuse. The subcutaneous version of the anti-CD38 mAb Darzalex Faspro daratumumab...
...IV Darzalex. Administration-related reactions also dropped from 34% to 13% with the subcutaneous version. IV Darzalex...
...to subcutaneous formulations using a recombinant human hyaluronidase enzyme (rHuPH20). Lauren Martz, Senior Editor Darzalex, daratumumab (JNJ-54767414, humax-cd38) Johnson...
BioCentury | Apr 14, 2020
Finance

COVID-19 pushes J&J to slash guidance; vaccine initiative on track

...pharmaceutical growth in the first quarter with sales rising 30% to $1.8 billion, while Darzalex daratumumab...
...same quarter last year, compared with Imbruvica sales of $1 billion. J&J has rights to Darzalex...
Items per page:
1 - 10 of 204